top of page

Select Publications

View a complete list in PubMed and Scopus


Woodford MR, Backe SJ, Wengert LA, Dunn DM, Bourboulia D, Mollapour M. Hsp90 chaperone code and the tumor suppressor VHL cooperatively regulate the mitotic checkpoint. Cell Stress Chaperones. 2021 Sep 29. doi:
10.1007/s12192-021-01240-2. Epub ahead of print. PMID: 34586601.


Truman AW, Bourboulia D, Mollapour M. Decrypting the chaperone code. J Biol Chem. 2021 Jan-Jun;296:100293. doi: 10.1016/j.jbc.2021.100293. Epub 2021 Feb 16.PMID: 33837727


Baker-Williams AJ, Hashmi F, Budzyński MA, Woodford MR, Gleicher S, HimanenSV, Makedon AM, Friedman D, Cortes S, Namek S, Stetler-Stevenson WG, Bratslavsky G, Bah A, Mollapour M, Sistonen L, Bourboulia D. Co-chaperones TIMP2 and AHA1Competitively Regulate Extracellular HSP90:Client MMP2 Activity and MatrixProteolysis. Cell Rep. 2019 Aug 13;28(7):1894-1906.e6. doi:10.1016/j.celrep.2019.07.045. PubMed PMID: 31412254.


Sánchez-Pozo J, Baker-Williams AJ, Woodford MR, Bullard R, Wei B, Mollapour M, Stetler-Stevenson WG, Bratslavsky G, Bourboulia D. Extracellular Phosphorylation of TIMP-2 by Secreted c-Src Tyrosine Kinase Controls MMP-2 activity. iScience 2018, 1, 87-96. 10.1016/j.isci.2018.02.004


Woodford MR, Dunn DM, Blanden AR, Capriotti D, Loiselle D, Prodromou C, Panaretou B, Hughes PF, Smith A, Ackerman W, Haystead TA, Loh SN, Bourboulia D, Schmidt LS, Marston Linehan W, Bratslavsky G, Mollapour M. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nat Commun. 2016 Jun 29;7:12037, PMID: 27353360


Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, Morgan RM, Prodromou C, Kron SJ, Panaretou B, Stetler-Stevenson WG, Landas SK, Neckers L, Bratslavsky G, Bourboulia D, Mollapour M. c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Rep. 2015 Aug 11;12(6):1006-1018, PMID: 26235616


Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. Mol Cell. 2014 Jan 23;53(2):317-329, PMID: 24462205


Han HY, Bourboulia D, Jensen-Taubman S, Isaac B, Wei B and Stetler-Stevenson WG. An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells. Oncogene 2014, 33, 1198-1206, advance online publication, March 11, 2013, PMID: 23474755


Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG. TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells. Oncotarget. 2013 Jan;4(1):166-176, PMID: 23371049


Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, Stetler-Stevenson WG. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother. 2012 Jul;35(6):502-512, PMID: 22735808

Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B and Stetler-Stevenson WG. Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment. Am J Pathol. 2011, 179, 2589-2600, PMID: 21933655


Reviews/Book chapters

Hashmi F, Mollapour M, Bratslavsky G, Bourboulia D. MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer. Urol Oncol. 2020 May 31:S1078-1439(20)30194-0. doi: 10.1016/j.urolonc.2020.04.034. Epub ahead of print. PMID: 32487351


Cortes S, Baker-Williams AJ, Mollapour M, Bourboulia DDetection and Analysis of Extracellular Hsp90 (eHsp90). Methods Mol Biol. 2018;1709:321-329. doi: 10.1007/978-1-4939-7477-1_23. PMID: 29177669


Chehab M, Caza T, Skotnicki K, Landas S, Bratslavsky G, Mollapour M, Bourboulia D. Targeting Hsp90 in urothelial carcinoma. Oncotarget. 2015 Apr 20;6(11):8454-8473, PMID: 25909217


Remillard T., Bratslavsky G., Jensen-Taubman S., Stetler-Stevenson W.G. and Bourboulia D. Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment. Molecular and Cellular Therapies 2014, 2, 17, PMID: 26056585


Abouelleil M, Bratslavsky G and Bourboulia D. Prostate Cancer Biomarkers – A Bench to Bedside perspective. Cancer Science and Research: Open Access 2014, 1, 3


Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M. Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. Future Med Chem. 2013 Jun;5(9):1059-1071, PMID: 23734688


Stetler-Stevenson W, Bourboulia D, Guedez L and Jensen-Taubman S. Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development. Current Angiogenesis 2012, 1, 148-156


Bourboulia D, Jensen-Taubman S and Stetler-Stevenson WG. TIMP-2 An Endogenous Angiogenesis Inhibitor with Distinct Antitumoral Properties. Treatment Strategies-Hemat. 2012, 2, 31-35


Bourboulia D, and Stetler-Stevenson WG. Matrix MetalloProteinases (MMPs) and Tissue Inhibitors of MetalloProteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010, 20, 161-168. PMID: 20470890

bottom of page